A First in human, Phase 1 Study to Evaluate the Safety of TTX 080, an HLA G Antagonist, in Subjects With Advanced Solid Tumors
For more information about the trial above please contact the study team:
Principal Investigator, John Kaczmar, at email@example.com, or please call +1 843-792-6691.
Study Coordinator, Carly Fecio, at firstname.lastname@example.org.
Trial opened at the following institutions: Medical University of South Carolina